The Australian share market finished with modest gains to close out its worst week since November.
The benchmark S&P/ASX200 index closed Friday up 16.3 points, or 0.25 per cent, to 6,584.4 points, while the broader All Ordinaries finished up 21.1 points, or 0.32 per cent, to 6,663.4 points.
For the week, the ASX200 ended down 184 points, making for its worst week since 191-point loss in mid-November.
The tech sector was the only one to move more than a percentage point, posting an overall gain of 1.3 per cent.
Afterpay rose 6.1 per cent to $24.17 after the buy-now, pay-later company said it now had more than two million US customers, up from 1.5 million in early June.
Wealth management software company Praemium was up 13.3 per cent, Wisetech Global rose 2.7 per cent and Altium was up two per cent.
James Hardie was the biggest ASX200 gainer, up 13.7 per cent to an 11-month high of $21.62 after the building materials company said it expected to make more profit this year than analysts had forecast.
AMP shot up 11.6 per cent to a three-week high of $1.93 after the fallen banking and wealth giant completed a $650 million capital raising to fund its three-year turnaround.
The big banks were mostly up, with Commonwealth gaining 0.6 per cent to $79.42, Westpac up 0.5 per cent to $28.21 and ANZ up 0.7 per cent to $27.
NAB was the outlier, declining 0.3 per cent to $27.65.
The mining sector was mixed despite a rise in the price of iron ore, with BHP down a single cent to $37.29, Rio Tinto down 0.9 per cent to $87.69 but South32 up 1.8 per cent to $2.88.
Brisbane-headquartered Argentinian lithium producer Orocobre was up 10.3 per cent to $3.01 after ground was broken on a lithium hydroxide plant in Japan it holds a 75 per cent stake in.
Goldminers were mostly down after several days of strong gains, even as the price of the precious metal stayed firm above $US1,500 an ounce.
Newcrest fell 0.6 per cent, Northern Star was down 2.4 per cent and Saracen dipped 2.6 per cent.
News Corp was up 1.3 per cent to $19.90 after the media company said it had achieved a $US228 million ($A423 million) full-year profit.
REA Group was up 5.6 per cent to $96.64 after announcing underlying profit rose 5.5 per cent to $295.5 million.
A number of companies will be reporting earnings include CSL, JH Hi-Fi, Challenger, Vicinity Centres, Evolution Mining, Orora and Pact Group.
US stocks have fallen following renewed jitters over the US-China trade war, capping a week of trading that saw big swings and high volume.
President Donald Trump said on Friday the US and China were pursuing trade talks but he was not ready to make a deal, fanning fears over the impact of the trade war on the global economy.
Trump also said the US would continue to refrain from doing business with Chinese telecoms equipment giant Huawei Technologies.
The week was marked by wild swings, but indexes finished nearly flat on the week. This week's volume on US exchanges was also the biggest weekly total of the year, exceeding 41 billion shares.
On Friday, all three indexes were down more than 1 per cent in early trading and rebounded later in the session, with the Dow briefly turning positive at one point. This left a 315-point swing between the blue-chip index's high and low of the day.
Shares of chipmakers and other tariff-sensitive technology companies fell, with the Philadelphia SE Semiconductor index down 1.8 per cent.
The Dow Jones Industrial Average on Friday fell 90.75 points, or 0.34 per cent, to 26,287.44; the S&P 500 lost 19.44 points, or 0.66 per cent, to 2,918.65; and the Nasdaq Composite dropped 80.02 points, or 1 per cent, to 7,959.14.
Shares of Amgen jumped 5.9 per cent after news that a US judge said patents relating to the Amgen's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis.
Uber Technologies shed 6.8 per cent after the ride-hailing company reported a record $US5.2 billion ($7.7 billion) quarterly loss and revenue that fell short of Wall Street targets.
Nektar Therapeutics shares also plunged, a day after the drug developer flagged manufacturing issues with its experimental cancer drug bempeg.